Nye legemidler som ikke har markedsføringstillatelse

For legemidler oppført på listen gjelder retningslinjens vilkår <u>uavhengig av indikasjon for bruken</u>.

Oppdatert: 20.06.2024

| Virkestoff | Indikasjon per nå. (Samt mulig andre indikasjoner i fremtiden.) | Orphan medicinal product (Se informasjon om COMP (Komiteen for legemidler mot sjeldne sykdommer) på www.legemi ddelverket.n o | Oppført på listen |
|---|--|---|----------------------|
| abicipar pegol | Treatment of neovascular (wet) age related macular degeneration | | |
| acalabrutinib | (AMD) Treatment of mantel cell lymphoma - Kun denne indikasjonen | | aug.19 mar.18 |
| acoramidis | Treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) | х | mar.24 |
| allogeneic bone marrow derived mesenchymal stromal cells, ex- vivo expanded | Treatment of graft-versus-host disease. | х | sep.23 |
| alpelisib | Treatment of patients with severe manifestations of PIK3CArelated overgrowth spectrum - Kun denne indikasjonen | х | aug.22 |
| apadamtase alfa | Treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency | х | jun.23 |
| arimoclomol | Treatment of Niemann-Pick disease type C (NPC) | х | des.20 |
| artesunate (*Kun styrken 60 mg) | Treatment of severe malaria | х | feb.21 |
| aumolertinib | Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer | | des.22 |
| autologous human chondrocytes in vitro expanded | Repair of cartilage defects of the knee joint | | sep.20 |

| autologous cartilage-derived | Repair of symptomatic, localised, full- | | |
|-----------------------------------|---|---|------------------|
| articular | thickness cartilage defects of the knee | | |
| chondrocytes, in-vitro expanded | joint grade III or IV | | |
| , , | | | jan.24 |
| autologous glioma tumor cells, | Treatment of glioma | | |
| inactivated / autologous glioma | | | |
| tumor cell lysates, inactivated / | | | |
| allogeneic glioma tumor cells, | | Х | |
| inactivated / allogeneic glioma | | | |
| tumor cell lysates, inactivated | | | okt.20 |
| bardoxolone methyl | Treatment of chronic kidney disease | | |
| | (CKD) | x | okt.21 |
| | | | /des.21 |
| belinostat | Relapserad/refraktärt T-cellslymfom | | mar.24 |
| belumosudil | versus host disease (GvHD) | | nov.22 |
| beremagene-geperpavec | Treatment of patients from birth with | | des.23 |
| | dystrophic | Х | /jun.23 |
| halatte. | Total and the first built and (DED) with | | /juii.23 |
| belzutifan | Treatment of adult patients with | | |
| | advanced renal | | jan.24 |
| | Treatment of neovascular (wet) | | |
| bevacizumab | age related macular degeneration | | |
| | (nAMD) - Kun denne indikasjonen | | feb.23 |
| capivasertib | Indicated in combination with | | |
| | fulvestrant for the treatment of adult | | |
| | patients with hormone receptor (HR) | | |
| | positive, human epidermal growth | | |
| | factor receptor 2 (HER2) negative | | |
| | (defined as IHC 0 or 1+, or IHC 2+/ISH-) | | |
| | locally advanced or metastatic breast | | |
| | cancer following recurrence or | | |
| | progression on or after an endocrine | | |
| | based regimen | | jun.23 |
| catumaxomab | Indicated for the treatment of malignant | | |
| | ascites | | mai.24 |
| concizumab | Indicated for routine prophylaxis to | | |
| | prevent or reduce the frequency of | | |
| | bleeding in patients with | | |
| | - haemophilia A (congenital factor VIII | | |
| | deficiency) with FVIII inhibitors ≥ 12 | | |
| | years of age haemophilia B (congenital | | |
| | factor IX deficiency) with FIX inhibitors | | |
| | of any age. | | f-1- 22 |
| a a sa a liada | Treatment of non-hodgkin lymphoma | | feb.23 mar.18 |
| copanlisib | Treatment of non-noughin lymphoma Treatment of adult patients with | | 11101.10 |
| conanlisih | · · | x | : 122 |
| copanlisib | marginal zone lymphoma | | jul.22 |
| crovalimah | Treatment of paroxysmal nocturnal | | ~= |
| crovalimab | haemoglobinuria | | aug.23 |

| daprodustat | Treatment of anemia assiciated with | | |
|------------------------------|--|---|----------------|
| | chronic kidney disease (CKD) in adults | | apr.22 |
| Datopotamab | | | |
| | Treatment of adult patients with locally | | |
| | advanced or metastatic non squamous | | |
| | nonsmall cell lung cancer (NSCLC) | | apr.24 |
| deferiprone | Treatment of neurodegeneration with | | |
| | brain iron accumulation - Kun denne | x | |
| | indikasjonen | | jun.19 |
| delandistrogene moxeparvovec | Treatment of Duchenne muscular | | |
| | dystrophy | | aug.23 |
| depatuximab mafodotin | Treatment of glioblastoma (GBM) | | nov.18 |
| deutivacaftor / tezacaftor | | | |
| /vanzacaftor Orphan | Indicated for the treatment of cystic | | |
| | fibrosis | | |
| diclofenamide | Treatment of periodic paralysis | | feb.19 |
| Diflunisal | Treatment of ATTR amyloidosis | х | mar.24 |
| Donanemab | To slow disease progression in adult | | |
| | patients with Alzheimer's disease (AD) | | mai.24 |
| duvelisib | Treatment of adult patients with small | | |
| | lymphocytic lymphoma (SLL) - Kun | х | |
| | denne indikasjonen | | feb.20 |
| edaravone | Amyotrophic lateral sclerosis (ALS) | | jan.18 |
| efanesoctocog alfa | Treatment and prophylaxis of bleeding | | |
| | in patients with haemophilia A | | jun.23 |
| eflornithine / sulindac | Treatment of familial adenomatous | | |
| | polyposis | Х | jul.20 |
| | Treatment of primary biliary cholangitis | | |
| elafibranor | (PBC) | Х | nov.23 |
| enasidenib | Treatment of acute myeloid leukaemia | | mar.18 |
| entolimod | | | |
| | Treatment of acute radiation syndrome | х | nov.17 |
| | | | |
| eplontersen | Treatment of adult patients with | | |
| | polyneuropathy associated with | | |
| | hereditary transthyretin-mediated | Х | |
| | amyloidosis (ATTRv) | | nov.23 |
| erdafitinib | Treatment of adults with locally | | |
| | advanced or metastatic urothelial | | nov.19, nov.23 |
| | carcinoma | | |
| ferric citrate coordination | Treatment of iron deficiency anaemia in | | |
| complex | adult chronic kidney disease (CKD) | | |
| | patients with elevated serum | | |
| | phosphorus levels | | jun.24 |
| ferumoxytol | Intravenous treatment of iron deficiency | | |
| | anaemia (IDA) | | jun.22 |
| fidanacogene elaparvovec | Indicated for the treatment of severe | | |
| - , | and moderately severe haemophilia B | Х | jun.23 |

| fruquintinib | Treatment of metastatic colorectal | | |
|---------------------------------------|--|---|----------|
| | cancer | | jul.23 |
| garadacimab | Routine prevention of attacks of | x | 122 |
| | hereditary angioedema (HAE) | | des.23 |
| glutamine | Treatment of sickle cell disease | | mar.18 |
| govorestat | Treatment of adults and | | |
| | children aged 2 years and older with a | x | |
| | confirmed diagnosis of classic | | |
| | galactosemia | | jan.24 |
| idebenone | Total and a formation and a formation to | | |
| | Treatment of respiratory dysfunction in | | |
| | patients with Duchenne muscular | x | |
| | dystrophy (DMD) not using | | |
| | glucocorticoids - Kun denne indikasjonen | | |
| | | | aug.19 |
| imetelstat | Treatment of adult patients with | | |
| | transfusion-dependent anaemia due to | | |
| | very low, low and intermediate-risk | х | |
| | myelodysplastic syndromes (MDS) with | | |
| | ring sideroblasts | | nov.23 |
| inavolisib | Treatment of adult patients with PIK3CA- | | |
| | mutated, hormone receptor (HR)- | | |
| | positive, human epidermal growth | | |
| | factor receptor 2 (HER2)-negative, | | |
| | locally advanced or metastatic breast | | |
| | cancer | | jun.24 |
| infigratinib | Treatment of cholangiocarcinoma | | |
| | | Х | des.21 |
| ipatasertib | Treatment of breastcancer | | mar.18 |
| lazertinib | Treatment of adult patients with | | |
| | advanced nonsmall cell lung cancer | | |
| | (NSCLC) | | mar.24 |
| lecanemab | Indicated as a disease modifying | | |
| | treatment in adult patients with Mild | | |
| | Cognitive Impairment due to | | |
| | Alzheimer's disease and Mild | | |
| | Alzheimer's disease (Early Alzheimer's | | |
| | disease) | | feb.23 |
| lenadogene nolparvovec | Treatment of vision loss due to Leber | | |
| , , , , , , , , , , , , , , , , , , , | Hereditary Optic Neuropathy (LHON) | Х | nov.20 |
| leniolisib | | | |
| | Treatment of activated phosphoinositide | x | |
| | 3-kinase delta syndrome (APDS) | ~ | nov.22 |
| linvoseltamab | Monotherapy for the treatment of adult | | |
| Oscitalilus | patients with relapsed or refractory | | |
| | multiple myeloma | | mar.24 |
| LUT014 | | | 11101.24 |
| LU 1014 | Topical BRAF Inhibitor Therapy for EGFR | | |
| | Inhibitor–Induced Acneiform Rash | | nov 22 |
| | | | nov.23 |

| macitentan / Tadalafil (kun | treatment of pulmonary arterial | Ī | |
|------------------------------|--|---|--------|
| denne spesifikk kombinasjon) | hypertension (PAH) in adult patients | | aug.23 |
| marstacimab | Indicated for routine prophylaxis of | | |
| | bleeding episodes in patients with | x | |
| | haemophilia A or haemophilia B | | nov.23 |
| mirvetuximab soravtansine | Treatment of ovarian, fallopian tube, or | | |
| | primary peritoneal cancer | Х | nov.23 |
| mobocertinib | Treatment of adult patients with | | |
| | epidermal growth factor receptor (EGFR) | | |
| | exon 20 insertion mutation-positive | | |
| | locally advanced or metastatic non-small | | |
| | cell lung cancer (NSCLC). | | jan.21 |
| mozafancogene autotemcel | Treatment of paediatric patients with | Х | |
| | Fanconi Anaemia Type A | ^ | mai.24 |
| naporafenib | Treatment of advanced solid tumours | | |
| | including ovarian cancer | | okt.21 |
| nedosiran | | | |
| | Til behandling av primær hyperoksaluri. | | mai.24 |
| nemolizumab | Treatment of moderate-to-severe atopic | | |
| | dermatitis and for the treatment of | | |
| | prurigo nodularis | | mar.24 |
| nirogacestat | Treatment of desmoid tumours | Х | apr.24 |
| obecabtagene autoleucel | Treatment of patients with relapsed or | | |
| | refractory B cell precursor acute | х | |
| | lymphoblastic leukaemia (ALL) | | mai.24 |
| obeticholic acid | Improvement of liver fibrosis and | | |
| | resolution of steatohepatitis in adult | | |
| | patients with significant liver fibrosis due | | |
| | to nonalcoholic steatohepatitis (NASH). | | |
| | Kun denne indikasjonen | | aug.20 |
| obnitix | Treatment of RR-aGVHD | | apr.24 |
| odevixibat | Treatment of cholestatic pruritus in | | |
| | Alagille syndrome (ALGS) Kun denne | | |
| | indikasjonen | | jan.24 |
| Odronextamab | Treatment of blood cancers (follicular | | |
| | lymphoma (FL) or diffuse large B cell | | |
| | lymphoma (DLBCL) and large B cell | | |
| | lymphoma) | | mai.24 |
| omadacycline tosylate | Treatment of community-acquired | | |
| | bacterial pneumonia (CABP) and acute | | |
| | bacterial skin and skin structure | | |
| | infections (ABSSSI) in adults | | okt.18 |
| omecamtiv mecarbil | | | |
| | Treatment of adult patients with | | |
| | symptomatic chronic heart failure and | | |
| | reduced ejection fraction less than 30% | | feb.23 |

| oportuzumab monatox | Treatment and prevention of recurrence | | |
|---------------------|---|---|----------|
| | of carcinoma-in-situ (CIS) of the urinary | | |
| | bladder and prevention of recurrence of | | |
| | high grade Ta and/or T1 papillary | | |
| | tumours | | apr.21 |
| parsaclisib | Treatment of adult patients with | | - 1 |
| paradensib | relapsed or refractory marginal zone | x | |
| | lymphoma (MZL) | ^ | feb.22 |
| pegcetacoplan | Treatment of geographic atrophy (GA) | | 100.22 |
| pegeetacopian | secondary to age-related macular | | |
| | degeneration (AMD) - Kun denne | х | |
| | indikasjonen | | feb.23 |
| pevonedistat | Higher-risk chronic myelomonocytic | | 100.23 |
| pevonedistat | leukemia (HR-CMML), low-blast acute | | |
| | myeloid leukemia (LB-AML) and higher | | |
| | risk myelodysplastic syndromes | | aug.20 |
| plazomicin | , , , , | | |
| piazomiem | Treatment of symptomatic tenosynovial | | |
| | giant cell tumor (TGCT), also known as | | |
| | pigmented villonodular synovitis (PVNS) | | |
| | and giant cell tumor of the tendon | | |
| | sheath (GCT-TS), where surgical | х | |
| | resection is potentially associated with | | |
| | worsening functional limitation or | | |
| | severe morbidity | | |
| | Severe morbialty | | mar.19 |
| plazomicin | Treatment of Complicated urinary tract | | Illai.13 |
| piazoiiiiciii | infection (cUTI), including | | |
| | pyelonephritis; treatment of | | |
| | Bloodstream infection (BSI); | | |
| | treatment of infections due to | | |
| | Enterobacteriaceae | | nov 10 |
| 111 | For the treatment of acanthamoeba | | nov.18 |
| polihexanide | keratitis | х | ium 22 |
| uon atuo atiu ih | Relatitis | | jun.22 |
| repotrectinib | Treatment of ROS1-positive locally | | |
| | advanced or | | |
| | metastatic non-small cell lung cancer | | |
| | (NSCLC) | | |
| | and for solid tumours; ROS1+ Advanced | | |
| | Non-Small Cell Lung Cancer (NSCLC) or | | ian 24 |
| | NTRK+ Advanced Solid Tumors | | jan.24, |
| | Treatment of adults with nonalcoholic | | nov.21 |
| resmetirom | steatohepatitis (NASH)/metabolic | | |
| | • | | |
| | dysfunctionassociated steatohepatitis | | an 24 |
| | (MASH) with liver fibrosis | | apr.24 |
| resminostat | Treatment of patients with advanced | | |
| | stage mycosis fungoides (MF) and Sézary | | |
| | syndrome (SS) | | apr.24 |

| retifanlimab | Treatment of locally advanced or | | |
|---|--|---|----------|
| retifalilifiab | metastatic squamous carcinoma of the | | |
| | anal canal (SCAC) who have progressed | | |
| | on or who are intolerant of platinum | Х | |
| | (kun denne indikasjonen) | | mar.21 |
| | Treatment of peripheral T-cell | | IIIdi.ZI |
| romidepsin | lymphoma | | |
| | 1 · · | | |
| | (PTCL) in adult patients who have | | |
| | received at least one prior therapy. | | feb.22 |
| rovalpituzumab tesirine | Small cell lung cancer (SCLC) | | jan.18 |
| savolitinib | monotherapy for the treatment of adult | | |
| | patients with relapsed or refractory | | |
| | multiple myeloma | | mar.23 |
| Seladelparlysindihydrat | | | |
| | A peroxisome proliferator receptor delta | | |
| | (PPAR δ) activator indicated for the | | |
| | treatment of primary biliary cholangitis | | |
| | (PBC) including pruritus in adults without | | |
| | cirrhosis or with compensated cirrhosis | | |
| | (Child-Pugh A) in combination with | | |
| | ursodeoxycholic acid (UDCA) who have | | |
| | an inadequate response to UDCA alone, | | |
| | or as monotherapy in those unable to | | |
| | tolerate UDCA. | | apr.24 |
| sepiapterin | Treatment of hyperphenylalaninemia | | арт.2 т |
| зеріарієнні | (HPA) in adult and paediatric patients | | |
| | with phenylketonuria (PKU) | | |
| | patients with phenylketonuria (PKU). | | iun 24 |
| and Park | First-line treatment of adult patients | | jun.24 |
| serplulimab | with extensive-stage small cell lung | | |
| | cancer (ES-SCLC) | X | 22 |
| | cancer (ES-SCLC) | | apr.23 |
| sipavibart | | | |
| | Pre-eksponeringsprofylakse mot covid- | | |
| | 19-sykdom hos spesielt sårbare grupper | | |
| | hvor vaksinasjon ikke gir tilstrekkelig | | |
| | beskyttelse mot alvorlig sykdom. | | mar.24 |
| siponimod | Indicated for the treatment of | | |
| | thrombocytopenia - Kun denne | | |
| | indikasjonen | | okt.18 |
| sodium phenylbutyrate/ | | | |
| ursodoxicoltaurine | Treatment of amyotrophic lateral | Х | |
| | sclerosis (ALS) | | apr.22 |
| sotatercept | Treatment of pulmonary arterial | | |
| ' | hypertension in adults | Х | sep.23 |
| sugemalimab | Treatment of non-small cell lung cancer | | · |
| J = 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | (NSCLC) | | mar.23 |
| surufatinib | Treatment of progressive | | 23 |
| Jai alatiiii) | neuroendocrine tumours | | jul.21 |
| tazamatastat | Treatment of malignant mesothelioma | | Jui.21 |
| tazemetostat | and Epithelioid sarcoma | | mai 21 |
| | and Epithenola Sarconia | | mai.21 |

| tegomil fumarat | Treatment of multiple sclerosis | | mai.24 |
|--------------------------|---|---|--------|
| teprotumumab | Treatment of moderate to severe | | |
| | Thyroid Eye Disease (TED) | | jun.24 |
| tiratricol | Treatment of monocarboxylate | | |
| | transporter 8 (MCT8) deficiency | Х | nov.23 |
| tisotumab vedotin | treatment of adult patients with | | |
| | recurrent or metastatic cervical cancer | | |
| | with disease progression on or after | | |
| | systemic therapy | | mar.24 |
| toripalimab | Combination treatment for metastatic | | |
| | or recurrent locally advanced | | |
| | nasopharyngeal carcinoma and for | | |
| | metastatic or recurrent oesophageal | | |
| | | | des.22 |
| trastuzumab duocarmazine | Treatment of HER2 (Human Epidermal | | |
| | Growth Factor Receptor 2)-positive | | |
| | metastatic breast | | aug.22 |
| troriluzole | | | |
| | Treatment of adult patients with | х | |
| | spinocerebellar ataxia genotype 3 (SCA3 | | nov.23 |
| valemetostat | | | |
| | Ved tilbakevendende/refraktær (R/R) | | |
| | adult T-cell leukemia/lymphoma (ATLL). | | apr.22 |
| Vorasidenib | Til behandling av gliom | | mai.24 |
| veliparib | Treatment of BRCA 1, BRCA 2, BARD1 | | |
| | and/orr PALB2 mutated cancer | | mar.18 |
| zolbetuximab | Treatment of locally advanced | | |
| | unresectable or metastatic HER2 | V | |
| | negative gastric or gastro-oesophageal | Х | |
| | junction (GEJ) adenocarcinoma | | aug.23 |